Episoder
-
In the final episode of this 2-part series, Jessica Seidelman, MD and Johannes Plate, MD, PhD conclude the conversation with Gina Suh, MD, Ken Urish, MD, PhD, and Ray Schuch, PhD on the topic of innovation in treatment of PJI's with phage lysins. Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, genex®, and SYNICEMTM, please click here
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD chat with Gina Suh, MD, Ken Urish, MD, PhD, and Ray Schuch, PhD in part 1 of this 2-part conversation on the topic of innovation in treatment of PJI's with phage lysins. Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, genex®, and SYNICEMTM, please click here
-
Mangler du episoder?
-
In the final episode of this 2-part series, Jessica Seidelman, MD and Johannes Plate, MD, PhD conclude the conversation with P. Maxwell Courtney, MD, Katherine Belden, MD, Poorani Sekar, MD on the topic of long term antibiotic usage at The International Consensus Meeting in Istanbul, Turkey, May 2025. Thanks to Peptilogics for sponsoring this episode. For more information about their clinical trials, email [email protected], or visit Peptilogics.com.
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD chat with P. Maxwell Courtney, MD, Katherine Belden, MD, and Poorani Sekar, MD in part 1 of this 2-part conversation on the topic of long term antibiotic usage at The International Consensus Meeting in Istanbul, Turkey, May 2025. Thanks to Peptilogics for sponsoring this episode. For more information about their clinical trials, email [email protected], or visit Peptilogics.com.
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
In the final episode of this 2-part series, Jessica Seidelman, MD and Johannes Plate, MD, PhD conclude the conversation with Michael Henry, MD and Daisuke Furukawa, MD on the topic of Suppressive Antibiotic Therapy (SAT) at The International Consensus Meeting in Istanbul, Turkey, May 2025. Thanks to bioMérieux for sponsoring this episode. For more information about their BIOFIRE® Joint Infection (JI) Panel and molecular diagnostics solutions, please visit bioMérieux.com.
-
Hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD chat with Michael Henry, MD and Daisuke Furukawa, MD in part 1 of this 2-part conversation on the topic of Suppressive Antibiotic Therapy at The International Consensus Meeting in Istanbul, Turkey, May 2025. Thanks to bioMérieux for sponsoring this episode. For more information about their BIOFIRE® Joint Infection (JI) Panel and molecular diagnostics solutions, please visit bioMérieux.com
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
In the final episode of this 2-part series, Jessica Seidelman, MD and Johannes Plate, MD, PhD conclude the conversation with Alaina Ritter, MD, Geno Tai, MD, and Sumon Nandi, MD on the topic of antibiotic duration following DAIR in PJI analyzed at The International Consensus Meeting in Istanbul, Turkey, May 2025. Here are the ICM links: DOCUMENTS | ICMORTHO. Thanks to bioMérieux for sponsoring this episode. For more information about their BIOFIRE® Joint Infection (JI) Panel and molecular diagnostics solutions, please visit bioMérieux.com.
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD chat with Alaina Ritter, MD, Geno Tai, MD, and Sumon Nandi, MD in part 1 of this 2-part conversation on the topic of antibiotic duration following DAIR in PJI analyzed at The International Consensus Meeting in Istanbul, Turkey, May 2025. Thanks to bioMérieux for sponsoring this episode. For more information about their BIOFIRE® Joint Infection (JI) Panel and molecular diagnostics solutions, please visit bioMérieux.com
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
In the final episode of this 2-part series, hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD conclude the conversation on Shoulder PJI definition evolution with Surena Namdari, MD, and Jason Hsu, MD. Thanks to bioMérieux for sponsoring this episode. For more information about their BIOFIRE® Joint Infection (JI) Panel and molecular diagnostics solutions, please visit bioMérieux.com.
-
Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they chat with Surena Namdari, MD, and Jason Hsu, MD in part 1 of this 2-part conversation on Shoulder PJI definition evolution. Thanks to bioMérieux for sponsoring this episode. For more information about their BIOFIRE® Joint Infection (JI) Panel and molecular diagnostics solutions, please visit bioMérieux.com.
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected].
-
Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss a challenging case with Meredith Schade, MD, and Stephanie Hawkins, MD. Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
In the conclusion of this series on long-acting antibiotics, hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they wrap up the conversation with Vance Fowler,MD, MHS, Thomas Holland, and Thomas Lodise, PharmD, PhD in the first episode of this three-part series. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com
FOLLOW us on X @jointapproachor Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they continue the in-depth discussion on long-lasting antibiotics with Vance Fowler,MD, MHS, Thomas Holland, and Thomas Lodise, PharmD, PhD in the second episode of this three-part series. Thanks to Osteal Therapeutics for sponsoring this episode.For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they have an in-depth discussion about long-lasting antibiotics with Vance Fowler, MD, MHS, Thomas Holland, MD, and Thomas Lodise, PharmD, PhD in the first episode of this three-part series. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
In this follow-up conversation from the International Consensus Meeting on Infection, hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD chat with Allison Lastinger, MD, FACP, and Ran Schwarzkopf, MD about the question: “How can we capture the physical and psychological impact of orthopedic infections on patients?”
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD conclude the discussion on spinal implant infections with Geno Tai, MD, and Francis Lovecchio, MD. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they discuss spinal implant infections with Gino Tai, MD, and Francis Lovecchio, MD in part 1 of this 2 part series. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss a challenging case with Angela Hewlett, MD, and Curtis Hartman, MD.
Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
-
Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. conclude this 3-part series with discussions on pipeline innovations and adjunctive strategies for treating challenging prosthetic joint infections. Topics include local antibiotic administration, phage therapy, and immunotherapy. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com
Listen to Breakpoints: The SIDP Podcast
References:
“Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388
“NDM-9 resistance to taniborbactam” PMID 36796395
“Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537
IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/
“Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126
“Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124
“Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938
“Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147
“A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157
-
Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. continue discussing long-acting antibiotics, systemic vs. oral antibiotics, and drug and dosing perspectives in episode 2 of this 3-part conversation. This episode is sponsored by BONESUPPORT™, makers of CERAMENT® G with Gentamicin. CERAMENT G is an FDA-designated breakthrough device offering proven bone remodeling with reliable elution of broad-spectrum Gentamicin. CERAMENT G has a 96% success rate in eradication of infection in a single-stage for patients with fracture related infections and chronic osteomyelitis. To learn more and review CERAMENT G cases, visit their website at BONESUPPORT.com
Listen to Breakpoints: The SIDP Podcast
References:
“Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388
“NDM-9 resistance to taniborbactam” PMID 36796395
“Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537
IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/
“Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126
“Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124
“Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938
“Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147
“A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157
FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]
- Se mer
